Work

Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)

Year: 2013

Type: article

Authors: Thomas Semlitsch, Klaus Jeitler

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute

Award: G666505512

OpenAlex ID: W37749742

FWCI:

Cites:

Cited by:

Related to: 10